Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $116,000.

  • 4D Molecular Therapeutics' Cash from Financing Activities fell 79.58% to $116,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $18.5 million, marking a year-over-year decrease of 94.57%. This contributed to the annual value of $337.2 million for FY2024, which is 115.04% up from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Cash from Financing Activities is $116,000, which was down 80.70% from $601,000 recorded in Q4 2024.
  • 4D Molecular Therapeutics' Cash from Financing Activities' 5-year high stood at $318.8 million during Q1 2024, with a 5-year trough of -$847,000 in Q1 2021.
  • Over the past 3 years, 4D Molecular Therapeutics' median Cash from Financing Activities value was $10.6 million (recorded in 2023), while the average stood at $54.9 million.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Cash from Financing Activities tumbled by 117.74% in 2021 and then spiked by 261,138.00% in 2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Cash from Financing Activities (Quarterly) stood at $116.1 million in 2021, then crashed by 98.24% to $2.0 million in 2022, then soared by 132.75% to $4.8 million in 2023, then tumbled by 87.38% to $601,000 in 2024, then slumped by 79.58% to $116,000 in 2025.
  • Its Cash from Financing Activities was $116,000 in Q3 2025, compared to $601,000 in Q4 2024 and $568,000 in Q3 2024.